tbuckley/cabot-search huggingface dataset:
Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
Authors: Harry Quon, Neha Vapiwala, Arlene Forastiere, Erin B. Kennedy, David J. Adelstein, Holly Boykin, Joseph A. Califano, F. Chris Holsinger, Brian Nussenbaum, David I. Rosenthal, Lillian L. Siu, John N. Waldron
Journal: Journal of Clinical Oncology (2017)

Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy in oropharyngeal squamous cell carcinoma (OPSCC) that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. After applying standard critical appraisal policy and endorsement procedures, ASCO chose to endorse the ASTRO guideline. Methods The ASTRO guideline was reviewed by ASCO content experts for clinical accuracy and by ASCO methodologists for developmental rigor. On favorable review, an ASCO Expert Panel was convened to review the guideline contents and recommendations. The ASCO guideline approval body, the Clinical Practice Guidelines Committee, approved the final endorsement. Results The ASCO Expert Panel determined that the ASTRO guideline recommendations, published in July 2017, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the ASTRO guideline and added minor qualifying statements. Recommendations Recommendations for the addition of systemic therapy to definitive radiotherapy in the treatment of OPSCC, postoperative radiotherapy with and without systemic therapy following primary surgery of OPSCC, induction chemotherapy in the treatment of OPSCC, and the appropriate dose, fractionation, and volume regimens with and without systemic therapy in the treatment of OPSCC are outlined for a variety of disease stages and clinical scenarios. ASCO Endorsement Panel qualifying statements and minor modifications were made to the ASTRO recommendations. The staging system that is referenced in these guidelines is the American Joint Committee on Cancer Staging Manual, 7th edition. Additional information is available at: www.asco.org/head-neck-cancer-guidelines and www.asco.org/guidelineswiki .
Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study
Authors: Martin C Tammemagi, Heidi Schmidt, Simon Martel, Annette McWilliams, John R Goffin, Michael R Johnston, Garth Nicholas, Alain Tremblay, Rick Bhatia, Geoffrey Liu, Kam Soghrati, Kazuhiro Yasufuku, David M Hwang, Francis Laberge, Michel Gingras, Sergio Pasian, Christian Couture, John R Mayo, Paola V Nasute Fauerbach, Sukhinder Atkar-Khattra, Stuart J Peacock, Sonya Cressman, Diana Ionescu, John C English, Richard J Finley, John Yee, Serge Puksa, Lori Stewart, Scott Tsai, Ehsan Haider, Colm Boylan, Jean-Claude Cutz, Daria Manos, Zhaolin Xu, Glenwood D Goss, Jean M Seely, Kayvan Amjadi, Harmanjatinder S Sekhon, Paul Burrowes, Paul MacEachern, Stefan Urbanski, Don D Sin, Wan C Tan, Natasha B Leighl, Frances A Shepherd, William K Evans, Ming-Sound Tsao, Stephen Lam
Journal: The Lancet Oncology (2017)
Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation
Authors: Mani Akhtari, Sarah A. Milgrom, Chelsea C. Pinnix, Jay P. Reddy, Wenli Dong, Grace L. Smith, Osama Mawlawi, Zeinab Abou Yehia, Jillian Gunther, Eleanor M. Osborne, Therese Y. Andraos, Christine F. Wogan, Eric Rohren, Naveen Garg, Hubert Chuang, Joseph D. Khoury, Yasuhiro Oki, Michelle Fanale, Bouthaina S. Dabaja
Journal: Blood (2017)
TCT-360 Acute outcomes of a novel self-expanding transcatheter heart valve
Authors: Ulrich Schäfer, Christian Butter, Lenard Conradi, Florian Deuschl, Lisa Voigtländer, Daniel Kalbacher, Frank Hoelschermann, Gritt Tambor, Hidehiro Kaneko, Albrecht Elsaesser, Torsten Schuetz
Journal: Journal of the American College of Cardiology (2017)
Morphology of Sarcomas Derived From Fibroblasts Previously Treated With 20-Methylcholanthrene in Vitro (Preliminary Report)
Authors: Anderson Nettleship
Journal: JNCI Journal of the National Cancer Institute (1943)

Morphology of Sarcomas Derived From Fibroblasts Previously Treated With 20-Methylcholanthrene in Vitro (Preliminary Report) Get access Anderson Nettleship Anderson Nettleship passed assistant surgeon (R) National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 5, June 1943, Pages 559–561, https://doi.org/10.1093/jnci/3.5.559 Published: 01 June 1943
Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
Authors: Heinz-Josef Lenz, Fang-Shu Ou, Alan P. Venook, Howard S. Hochster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Charles David Blanke, Tyler Zemla, Xueping Qu, Federico Innocenti, Omar Kabbarah
Journal: Journal of Clinical Oncology (2017)

3511 Background: CALGB 80405 was a randomized Ph3 trial showing no OS or PFS difference in mCRC pts treated with Bevacizumab (BV) or Cetuximab (Cet) in the first line. A Nanostring platform was used to determine the CMS classification of 392 KRAS wt (codon 12 and 13) primary tumors and correlated it with OS and PFS in patients enrolled in 80405. Methods: CMS for 392 of 431tumors were defined using a custom CRC Nanostring panel (39 CMS classification not possible). Stratified Cox proportional hazard model was used to evaluate the effect of CMS classification stratified by prior radiation, prior chemotherapy, adjusting for age, sex, race, primary in place, liver met only, and sidedness. Results: We found CMS1 (14%), CMS2 (47%), CMS3 (2%), CMS4 (29%), NonConsensus (8%). Results are shown in Table 1. Patients with CMS1 who received BV had significantly longer OS than those who received Cet (HR 0.47, 95% CI [0.24, 0.92]). Patients with CMS2 who received BV tended to have shorter OS than those who received Cet (HR 1.41, CI [0.95, 2.08]). Conclusions: Our data suggest that CMS is associated with OS and PFS in first line therapy in mCRC patients. Preliminary data suggest that certain CMS may be associated with efficacy of Bev and Cet based chemotherapy. CMS classification should be explored as a stratification factor in future trials. Support: U10CA180821, U10CA180830, U10CA180882 Clinical trial information: NCT00265850. [Table: see text]
Meeting Update—World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017
Authors: Jaclyn J Renfrow, Michael Weller, Roy E Strowd
Journal: Neuro-Oncology (2017)

The 5 th quadrennial World Federation of Neuro-Oncology Societies (WFNOS) Meeting occurred in Zurich, Switzerland from May 4-7, 2017.The meeting featured 917 participantseople from 51 countries in attendance with the highest representation from the United States and Germany.Over 430 attendees participated in the preceding education day, organized by the European Association of Neuro-Oncology (EANO) and the EORTC Brain Tumor Group, with a new World Health Organization (WHO) brain tumor classification clinical focus in the morning sessions and a focus on genetic and metabolic therapeutic targets in the afternoon.Abstract submissions included 452 accepted abstracts, which were published in Neuro-Oncology, Volume 19, Supplement 3, May 2017.In addition, the meeting featured 77 oral presentations.Keynote addresses were provided by the major charter societies to the WFNOS including EANOthe European Association of Neuro-Oncology ("Current concepts and challenges of trial design in brain and leptomeningeal metastasis" by Dr. Riccardo Soffietti), ASNO ("hTERT in glioma -a multifaceted demigod" by Dr. Koichi Ichimura), and SNO ("Immunotherapy: advances and future directions" by Dr. David Reardon).In closing remarks, Dr. Michael Weller of Zurich passed the role of
TCT-748 Long term outcome after revascularization of long coronary artery lesions with very long or overlapping stents. Insights from the propensity score matched registry
Authors: Piotr Buszman, Bartlomiej Orlik, Mateusz Kachel, Aleksandra Kolarczyk-Haczyk, Łukasz Konarski, Katarzyna Czerwińska-Jelonkiewicz, Adam Janas, Aleksandra Chorianopoulos, Aleksander Zurakowski, Paweł Buszman, Krzysztof Milewski
Journal: Journal of the American College of Cardiology (2017)
PS02.26 Multifocal Adenocarcinoma of the Lung: Factors Predictive for Local Therapy
Authors: M.J. Mooradian, M. Price, A. Muzikansky, I. Lennes, M. Lanuti, H. Willers, S. Digumarthy, L.V. Sequist
Journal: Journal of Thoracic Oncology (2017)
Nuclear Wiskott–Aldrich syndrome protein co-regulates T cell factor 1-mediated transcription in T cells
Authors: Nikolai V. Kuznetsov, Bader Almuzzaini, Joanna S. Kritikou, Marisa A. P. Baptista, Mariana M. S. Oliveira, Marton Keszei, Scott B. Snapper, Piergiorgio Percipalle, Lisa S. Westerberg
Journal: Genome Medicine (2017)

The Wiskott–Aldrich syndrome protein (WASp) family of actin-nucleating factors are present in the cytoplasm and in the nucleus. The role of nuclear WASp for T cell development remains incompletely defined. We performed WASp chromatin immunoprecipitation and deep sequencing (ChIP-seq) in thymocytes and spleen CD4+ T cells. WASp was enriched at genic and intergenic regions and associated with the transcription start sites of protein-coding genes. Thymocytes and spleen CD4+ T cells showed 15 common WASp-interacting genes, including the gene encoding T cell factor (TCF)12. WASp KO thymocytes had reduced nuclear TCF12 whereas thymocytes expressing constitutively active WASpL272P and WASpI296T had increased nuclear TCF12, suggesting that regulated WASp activity controlled nuclear TCF12. We identify a putative DNA element enriched in WASp ChIP-seq samples identical to a TCF1-binding site and we show that WASp directly interacted with TCF1 in the nucleus. These data place nuclear WASp in proximity with TCF1 and TCF12, essential factors for T cell development.
Coccidioidomycosis—Arizona, 1990-1995
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Renaissance or requiem?
Authors: Kamran Abbasi
Journal: BMJ (2017)

Fifteen years ago Martin Marshall and Martin Roland asked whether the Quality and Outcomes Framework (QOF) would bring a renaissance or requiem for general practice in England.1 The mood is sombre, if not quite a requiem, but it’s hard to pin the blame entirely on QOF. The pay for performance scheme contributed by burdening general practitioners with administrative demands, diverting attention from interpersonal elements of care to financial incentives, and favouring poorly evidence based or managerial (over clinical) agendas. However, QOF delivered some “modest improvements in some aspects of clinical care,” Marshall and Roland now …
China celebrates better access to healthcare at Communist Party congress
Authors: Michael Woodhead
Journal: BMJ (2017)

Universal healthcare cover and the creation of a primary care system were two of the landmark achievements being celebrated at China’s 19th National Congress of the Communist Party, held in Beijing on 22 October.

Ms Li Bin, director of the National Health and Family Planning Commission, told the congress that the nation had implemented major reforms over the past five years to achieve what she called “a basic healthcare system with Chinese characteristics.”

Speaking at a media briefing at the congress, she noted that 95% of China’s population were now covered by basic health insurance and that people paid only about 30% of medical fees from their own pocket, down from …
A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses
Authors: Chenguang Shen, Junyu Chen, Rui Li, Mengya Zhang, Guosong Wang, Svetlana Stegalkina, Limin Zhang, Jing Chen, Jianli Cao, Xingjian Bi, Stephen F. Anderson, Timothy Alefantis, Minwei Zhang, Xiaoyang Cai, Kunyu Yang, Qingbing Zheng, Mujing Fang, Hai Yu, Wenxin Luo, Zizheng Zheng, Quan Yuan, Jun Zhang, James Wai-Kuo Shih, Harry Kleanthous, Honglin Chen, Yixin Chen, Ningshao Xia
Journal: Science Translational Medicine (2017)

A cross-lineage therapeutic antibody potently targets the receptor binding site of influenza B virus via multiple mechanisms.
Lack of data sharing in observational studies
Authors: Laura McDonald, Anna Schultze, Alex Simpson, Sophie Graham, Radek Wasiak, Sreeram V Ramagopalan
Journal: BMJ (2017)

Several articles call for the sharing of clinical trial data,12 but sharing observational data receives little—and arguably insufficient—attention. This is despite the important uses of these data, for example in assessing the weekend effect in the UK3 and in national clinical guidelines.4 …
Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature
Authors: Silvia Uccella, Annika Blank, Roberta Maragliano, Fausto Sessa, Aurel Perren, Stefano La Rosa
Journal: Endocrine Pathology (2017)
TCT-222 Combined and independent impact of diabetes mellitus and chronic kidney disease on clinical outcomes by SYNTAX score in patients undergoing PCI
Authors: Birgit Vogel, Usman Baber, Samantha Sartori, Jaya Chandrasekhar, Serdar Farhan, Sabato Sorrentino, Jason Kovacic, Nitin Barman, Zhen Ge, Srushti Shah, Pooja Vijay, Joseph Sweeny, Pedro Moreno, George Dangas, Roxana Mehran, Annapoorna Kini, Samin Sharma
Journal: Journal of the American College of Cardiology (2017)
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
Authors: Louisa Degenhardt, Amy Peacock, Samantha Colledge, Janni Leung, Jason Grebely, Peter Vickerman, Jack Stone, Evan B Cunningham, Adam Trickey, Kostyantyn Dumchev, Michael Lynskey, Paul Griffiths, Richard P Mattick, Matthew Hickman, Sarah Larney
Journal: The Lancet Global Health (2017)

Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15-64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID.
A Review of Automated Methods for Detection of Myocardial Ischemia and Infarction Using Electrocardiogram and Electronic Health Records
Authors: Sardar Ansari, Negar Farzaneh, Marlena Duda, Kelsey Horan, Hedvig B. Andersson, Zachary D. Goldberger, Brahmajee K. Nallamothu, Kayvan Najarian
Journal: IEEE Reviews in Biomedical Engineering (2017)

There is a growing body of research focusing on automatic detection of ischemia and myocardial infarction (MI) using computer algorithms. In clinical settings, ischemia and MI are diagnosed using electrocardiogram (ECG) recordings as well as medical context including patient symptoms, medical history, and risk factors-information that is often stored in the electronic health records. The ECG signal is inspected to identify changes in the morphology such as ST-segment deviation and T-wave changes. Some of the proposed methods compute similar features automatically while others use nonconventional features such as wavelet coefficients. This review provides an overview of the methods that have been proposed in this area, focusing on their historical evolution, the publicly available datasets that they have used to evaluate their performance, and the details of their algorithms for ECG and EHR analysis. The validation strategies that have been used to evaluate the performance of the proposed methods are also presented. Finally, the paper provides recommendations for future research to address the shortcomings of the currently existing methods and practical considerations to make the proposed technical solutions applicable in clinical practice.
Cardiomyocyte proliferation prevents failure in pressure overload but not volume overload
Authors: Karl Toischer, Wuqiang Zhu, Mark Hünlich, Belal A. Mohamed, Sara Khadjeh, Sean P. Reuter, Katrin Schäfer, Deepak Ramanujam, Stefan Engelhardt, Loren J. Field, Gerd Hasenfuss
Journal: Journal of Clinical Investigation (2017)

Induction of the cell cycle is emerging as an intervention to treat heart failure. Here, we tested the hypothesis that enhanced cardiomyocyte renewal in transgenic mice expressing cyclin D2 would be beneficial during hemodynamic overload. We induced pressure overload by transthoracic aortic constriction (TAC) or volume overload by aortocaval shunt in cyclin D2-expressing and WT mice. Although cyclin D2 expression dramatically improved survival following TAC, it did not confer a survival advantage to mice following aortocaval shunt. Cardiac function decreased following TAC in WT mice, but was preserved in cyclin D2-expressing mice. On the other hand, cardiac structure and function were compromised in response to aortocaval shunt in both WT and cyclin D2-expressing mice. The preserved function and improved survival in cyclin D2-expressing mice after TAC was associated with an approximately 50% increase in cardiomyocyte number and exaggerated cardiac hypertrophy, as indicated by increased septum thickness. Aortocaval shunt did not further impact cardiomyocyte number in mice expressing cyclin D2. Following TAC, cyclin D2 expression attenuated cardiomyocyte hypertrophy, reduced cardiomyocyte apoptosis, fibrosis, calcium/calmodulin-dependent protein kinase IIδ phosphorylation, brain natriuretic peptide expression, and sustained capillarization. Thus, we show that cyclin D2-induced cardiomyocyte renewal reduced myocardial remodeling and dysfunction after pressure overload but not after volume overload.
Disappearance of Intravenously Injected Methylcholanthrene in Mice of Different Susceptibility to Pulmonary Tumors
Authors: Egon Lorenz, Michael B. Shimkin
Journal: JNCI Journal of the National Cancer Institute (1942)

Journal Article Disappearance of Intravenously Injected Methylcholanthrene in Mice of Different Susceptibility to Pulmonary Tumors Get access Egon Lorenz, Egon Lorenz senior biophysicist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin Michael B. Shimkin assistant surgeon National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 5, April 1942, Pages 491–498, https://doi.org/10.1093/jnci/2.5.491 Published: 01 April 1942
Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor
Authors: Tomasz Maj, Wei Wang, Joel Crespo, Hongjuan Zhang, Weimin Wang, Shuang Wei, Lili Zhao, Linda Vatan, Irene Shao, Wojciech Szeliga, Costas Lyssiotis, J Rebecca Liu, Ilona Kryczek, Weiping Zou
Journal: Nature Immunology (2017)
O controle das doenças transmissíveis em trabalhadores immigrantes agrícolas temporais : estudo de casos na Noruega
Authors: P J Guérin, L Vold, P Aavitsland
Journal: Eurosurveillance (2005)

A informacao sobre o estado sanitario dos trabalhadores immigrantes agricolas temporais na Europa e rara. O accesso a atencao sanitaria desta populacao depende das leis nacionais e de seu estatuto legal no pais que os acolhe. Este artigo descreve um estudo de casos de um surto de samonellose na Noruega e os problemas encontrados a hora de complir as medidas de controle especificas nesta populacao de trabalhadores. E importante que a vigilância e o controle das doencas infecciosas tenham um apoio legislativo que permita applicar as medidas de controle. Apesar dos esforcos feitos para melhorar o direito dos trabalhadores immigrantes em termos de saude, estes trabalhadores seguem sendo “marginais” para estas medidas. E preciso prestar uma atencao especial a este grupo de populacao desfavorecido em termos de direitos sociais e sanitarios. Deveriam ser melhorados os planos de preparacao para lutar contra os patogenos transmissiveis que envolvem estas populacoes temporarias.
A phase 1b study to evaluate TAK-659 in combination with nivolumab in patients (pts) with advanced solid tumors.
Authors: Dejan Juric, Stephanie Faucette, Ling Wang, Huifeng Niu, Karuppiah Kannan, Kate Stumpo, Yuanxin Rong, Yaping Shou, John J. Nemunaitis
Journal: Journal of Clinical Oncology (2017)

TPS3104 Background: TAK-659 is an investigational, reversible, potent dual inhibitor of SYK and FLT-3. In ongoing early-phase studies (NCT02000934; NCT02323113), TAK-659 demonstrated an acceptable pharmacokinetic and safety profile, with evidence of preliminary activity in pts with DLBCL, follicular lymphoma, CLL, and AML (Kaplan et al. Blood 2016;128:624/2834). In preclinical studies, TAK-659 in combination with nivolumab, an anti-PD-1 checkpoint inhibitor, resulted in loss of myeloid suppressor cells (MDSCs), increased T-cell activation, and complete tumor growth suppression (Kannan et al. Eur J Cancer 2016;69:S92). This first-in-human combination study will investigate the efficacy and safety of TAK-659 and nivolumab in pts with advanced solid tumors. Methods: This open-label, multicenter, phase 1b study (NCT02834247) will include dose-escalation and expansion phases. Pts with advanced solid tumors who have failed ≥1 prior lines of therapy and have no effective therapeutic options available by investigator assessment will be eligible for the dose-escalation phase. Pts will receive oral TAK-659 at doses of 60–100 mg QD in a standard 3+3 schema, plus nivolumab 3 mg IV on days 1 and 15 of 28-day cycles. The expansion phase at the recommended phase 2 dose (RP2D) will include 3 cohorts of pts with relapsed/refractory metastatic triple-negative breast cancer, locally advanced/metastatic NSCLC, or locally advanced/metastatic head and neck squamous cell carcinoma (n = 30 response-evaluable pts in each cohort; 24 naïve, 6 relapsed/refractory to prior anti-PD-1/PD-L1 therapy). Ten pts in each cohort will receive 2 weeks of single-agent TAK-659 before starting combination therapy; the other 20 pts will receive combination therapy throughout. The primary endpoints are maximum tolerated dose/RP2D (dose-escalation phase) and overall response rate by investigator per RECIST v1.1 (expansion phase). Secondary endpoints include adverse events, disease control rate, duration of response, progression-free survival, overall survival, and TAK-659 pharmacokinetics. There are currently 7 pts enrolled; recruitment to the 100 mg dose-escalation cohort is ongoing. Clinical trial information: NCT02834247.